Coronavirus disease

aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications

Retrieved on: 
Monday, March 15, 2021
Medical specialties, Clinical medicine, Medicine, Immunology, Abdominal pain, Sarcoidosis, aTyr Pharma, Coronavirus disease, Cytokine

ATYR1923 reduced key inflammatory cytokines that are implicated in sarcoidosis and other ILDs, consistent with findings from animal models.

Key Points: 
  • ATYR1923 reduced key inflammatory cytokines that are implicated in sarcoidosis and other ILDs, consistent with findings from animal models.
  • Patients treated with ATYR1923 demonstrated a trend of overall improvement in key biomarkers analyzed compared to placebo.
  • aTyr recently completed enrollment in a proof-of-concept Phase 1b/2a trial evaluating ATYR1923 in patients with pulmonary sarcoidosis.
  • In response to the COVID-19 pandemic, aTyr completed a Phase 2 clinical trial with ATYR1923 in COVID-19 patients with severe respiratory complications.

UK Clinical Trial Confirms SaNOtize’s Breakthrough Treatment for COVID-19

Retrieved on: 
Monday, March 15, 2021
Health, Infectious diseases, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Health sciences, Medicine, Health, Clinical research, Antiviral drugs, COVID-19 drug development, Clinical trials, Coronavirus disease, Public health, Monoclonal antibody, Placebo-controlled study, Placebo, SaNOtize, Dr Stephen Winchester MSc MB BS FRCPath, Robert Wilson

In a randomized, double-blind, placebo-controlled Phase 2 trial that evaluated 79 confirmed cases of COVID-19, SaNOtizes early treatment for COVID-19 significantly reduced the level of SARS-CoV-2, including in patients with high viral loads.

Key Points: 
  • In a randomized, double-blind, placebo-controlled Phase 2 trial that evaluated 79 confirmed cases of COVID-19, SaNOtizes early treatment for COVID-19 significantly reduced the level of SARS-CoV-2, including in patients with high viral loads.
  • There were no adverse health events recorded in the UK trial, or in over 7,000 self-administered treatments given in earlier Canadian clinical trials.
  • NONS is the only novel therapeutic treatment so far proven to reduce viral load in humans that is not a monoclonal antibody treatment.
  • The results of the UK trial corroborate the information gathered from SaNOtizes earlier Phase 2 trials in Canada and independent lab tests at Utah State Universitys Antiviral Research Institute.

Quantum Leap Healthcare Collaborative Concludes Apremilast Not Likely to Reduce Time to Recovery or Mortality in Critically Ill Patients in I-SPY COVID Trial

Retrieved on: 
Friday, March 12, 2021
Medical specialties, Health, Phthalimides, Acetamides, Amgen, Apremilast, Intensive care medicine, Coronavirus disease, Mechanical ventilation

SAN FRANCISCO, March 12, 2021 /PRNewswire/ --Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, announced that apremilast (Otezla), made by Amgen, has been dropped for futility.

Key Points: 
  • SAN FRANCISCO, March 12, 2021 /PRNewswire/ --Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, announced that apremilast (Otezla), made by Amgen, has been dropped for futility.
  • The I-SPY COVID Trial is a phase II, open label, adaptive platform trial being conducted in critically ill COVID-19 patients who are receiving high flow oxygen or mechanical ventilation.
  • Patients assigned to the apremilast arm received backbone therapy in combination with 30 mg twice daily of apremilast for up to 14 days.
  • Under the terms of the collaboration agreement, Quantum Leap Healthcare Collaborative is the trial sponsor and manages all study operations.

Todos Medical Announces $7.2M in Sales for February 2021, a 38% Month Over Month Increase From Sales of $5.2M in January 2021

Retrieved on: 
Friday, March 12, 2021
COVID-19 testing, OTC Markets Group, Coronavirus disease, Articles, Medicine, Health

Additionally, Todos expects another one of its pending NYC Tri-State Area clients to become operational and begin to bring sample processing in-house in the coming weeks.

Key Points: 
  • Additionally, Todos expects another one of its pending NYC Tri-State Area clients to become operational and begin to bring sample processing in-house in the coming weeks.
  • For information related to Todos Medicals COVID-19 testing capabilities, please visit www.todoscovid19.com
    For testing and PPE inquiries, please email [email protected].
  • Headquartered in Rehovot, Israel, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers.
  • Todos has formed a strategic partnership with Integrated Health LLC to deploy mobile COVID-19 testing in the United States.

myLAB Box Launches 16 New At-Home Tests, Offering Comprehensive Health Monitoring from the Comfort of Home

Retrieved on: 
Thursday, March 11, 2021
Articles, Brand, Communication design, Graphic design, Product management, Coronavirus disease, Business, Health

As a result, they've missed critical health screenings or have health issues that have gone untreated.

Key Points: 
  • As a result, they've missed critical health screenings or have health issues that have gone untreated.
  • The CDC reports that four in 10 U.S. adults reported avoiding medical care because of concerns related to COVID-19.
  • With this in mind, myLAB Box is expanding its brand to focus on total body health.
  • By offering 16 new at-home testing options, myLAB Box allows consumers to take full control of their overall health from the comfort of home.

ACLIV Wins Certification for Killing COVID-19 Virus by 99.9% Within 30 Minutes From Antiviral Testing Agency in France

Retrieved on: 
Thursday, March 11, 2021
Research, Mobile, Wireless, Hardware, Pharmaceutical, Technology, Medical devices, Infectious diseases, Semiconductor, Science, Chemicals, Plastics, Other Technology, Health, Manufacturing, Zoonoses, Health, Articles, Pandemics, Antiviral drug, Biocides, Virus, Coronavirus disease, Influenza A virus subtype H1N1

: 21-1634) from an antiviral testing agency in France, confirming that its antiviral film ACLIV can kill COVID-19 virus by 99.9% within 30 minutes.

Key Points: 
  • : 21-1634) from an antiviral testing agency in France, confirming that its antiviral film ACLIV can kill COVID-19 virus by 99.9% within 30 minutes.
  • At the test conducted targeting the COVID-19 virus, ACLIV antiviral film killed 99.9% of the virus within 30 minutes.
  • This is by far the most outstanding result among those of antiviral tests conducted on the COVID-19 virus so far.
  • Previously, Hexis of France had produced the best result of killing the virus in approximately one hour.

UVDI V-MAX™ UV-C Technology Proven to Eliminate 99.99% of Airborne SARS-CoV-2 in Moving Airstream HVAC Testing

Retrieved on: 
Thursday, March 11, 2021
Building Systems, Commercial Building & Real Estate, Construction & Property, Manufacturing, Technology, General Health, Infectious diseases, Environment, Other Technology, Other Manufacturing, Science, Other Science, Health, Architecture, Research, Sarbecovirus, Zoonoses, Animal diseases, Medical specialties, Ultraviolet radiation, Animal virology, Bat virome, ASHRAE, Coronavirus disease, Ultraviolet, Coronavirus, Coronavir

UltraViolet Devices, Inc. (UVDI) announced its V-MAX UV-C air disinfection technology has achieved 99.99% inactivation of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in a single-pass in moving airstream HVAC testing.

Key Points: 
  • UltraViolet Devices, Inc. (UVDI) announced its V-MAX UV-C air disinfection technology has achieved 99.99% inactivation of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in a single-pass in moving airstream HVAC testing.
  • (Photo: Business Wire)
    In the independent testing, UVDI V-MAX UV-C air disinfection technology eliminated 99.99% of SARS-CoV-2 in a single pass at an airflow rate of 500 feet per minute.
  • To confirm effectiveness against airborne SARS-CoV-2 in a moving airstream, Innovative Bioanalysis used a HVAC duct test based on a modified ISO 15714 and ASHRAE 185.1 standard.
  • This novel testing underlines UVDIs UV-C technologys effectiveness against airborne SARS-CoV-2, stated Dr. Ashish Mathur, Ph.D., UVDI Vice President of Innovation and Technology.

AIM ImmunoTech to Present at the Q1 Virtual Investor Summit on March 24th

Retrieved on: 
Thursday, March 11, 2021
Sarbecovirus, Respiratory diseases, Zoonoses, Stock market, Animal diseases, Coronavirus disease, Occupational safety and health, Public health, Severe acute respiratory syndrome coronavirus, Microcap stock, Severe acute respiratory syndrome

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.

Key Points: 
  • The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.
  • The Q1 Investor Summit will take place virtually, featuring 100 companies and over 300 institutional and retail investors.
  • To request complimentary investor registration: please visit the following website at www.investorsummitgroup.com
    therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.

Businessman Ismail Sirdah explains What to Expect in Event Marketing in 2021 after New CDC Guidelines for Vaccinated People

Retrieved on: 
Thursday, March 11, 2021
Medical specialties, Articles, Coronavirus disease, Occupational safety and health, Public health, Zoonoses, Vaccine, Hybrid event, Health

The impact of COVID vaccines and the new guidelines that the CDC has released have a positive impact on live events and concerts.

Key Points: 
  • The impact of COVID vaccines and the new guidelines that the CDC has released have a positive impact on live events and concerts.
  • The truth is, no one knows for sure when or how event planning will return to a pre-COVID "normal."
  • Thankfully, there are ways that event planners can still get the job done while remaining flexible to current constraints, according to Ismail Sirdah.
  • Thanks to hybrid event Marketing technology, planners can retain attendance while keeping in-person events localized to communities, says Ismail Sirdah.

New study in Quebec long-term care facilities to investigate the science behind why so many residents had severe cases of COVID-19

Retrieved on: 
Thursday, March 11, 2021
Coronavirus disease, Occupational safety and health, Public health, Zoonoses, Movimiento Nacional de Trabajadores Para La Liberación, Psychosocial, Articles, Health sciences, Academic disciplines

Our study brings together immunological, biochemical, and psychosocial expertise to identify key factors that determine severe COVID-19 symptoms and complications in the elderly.

Key Points: 
  • Our study brings together immunological, biochemical, and psychosocial expertise to identify key factors that determine severe COVID-19 symptoms and complications in the elderly.
  • The hope is to help avoid unnecessary hospitalization and in so doing, reduce the use of health care resources.
  • The study is being carried out in partnership with two health networks (CIUSSS Centre Sud and CIUSSS de lOuest-de-lle-de-Montral).
  • The study aims to recruit 850 participants in public residential and long-term care facilities and in private seniors homes in Montreal.